

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

06 Jul 2026

### A clinical trial to compare the effect of high dose zinc sulphate and placebo on ulcer size of patients with peptic and jejunal ulcer

#### Protocol summary

##### Summary

So far, specific dose of zinc sulphate for peptic ulcer healing has not been proved in any study. In the only study conducted in Iran, certain outcome has not been achieved and just increasing the dose of zinc sulfate is recommended. This study wants to determine the effect of high doses of zinc sulfate on peptic and jejunal ulcer. A total of 90 patients who were admitted to the endoscopy clinic of gastrointestinal department of Sanandaj Tohid Hospital and fulfilled the inclusion criteria randomly divided into two intervention and control groups using block randomization with block sizes of 4. Patients and researcher were unaware of the grouping. Presence of peptic and jejunal ulcer in these patients has been proved by subspecialist of gastroenterology via endoscopy. Ulcer size was determined by subspecialist of gastroenterology via endoscopy unit. Patients and researcher were unaware of the grouping. Inclusion criteria was presence of peptic ulcer during endoscopy and exclusion criteria were presence of clear symptoms indicating malignancy in observation, evidence of ulcer malignancy in pathology result, patient reluctance to endoscopy, patients reluctance to continue taking drugs, drug discontinuation more than two days, diseases that impair absorption ( cirrhosis, celiac disease). In the intervention group zinc sulfate 220 mg capsules (Alhavi Pharmaceutical Company) gave to patients daily and in control group patients take placebo. Both the drug and placebo were in the same packages and gave to patients by clinic nurse who is aware of patient grouping. Patients` phone number was taken and to ensure that patients taking zinc sulfate telephone follow-up was performed weekly.

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT2014062212789N4**

Registration date: **2014-10-06, 1393/07/14**

Registration timing: **registered\_while\_recruiting**

Last update:

Update count: **0**

##### Registration date

2014-10-06, 1393/07/14

##### Registrant information

###### Name

Masoud Rasolabady

###### Name of organization / entity

###### Country

Iran (Islamic Republic of)

###### Phone

+98 87 3366 4654

###### Email address

rasolabady@muk.ac.ir

##### Recruitment status

###### Recruitment complete

##### Funding source

Vice Chancellor for Research, Kurdistan University of Medical Sciences

##### Expected recruitment start date

2014-07-06, 1393/04/15

##### Expected recruitment end date

2015-01-20, 1393/10/30

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

A clinical trial to compare the effect of high dose zinc sulphate and placebo on ulcer size of patients with peptic and jejunal ulcer

**Public title**

Effect of zinc sulphate on peptic and jejunal ulcer

**Purpose**

Treatment

**Inclusion/Exclusion criteria**

Inclusion criteria: presence of peptic ulcer during endoscopy Exclusion criteria: presence of clear symptoms indicating malignancy in observation, presence of malignancy in pathology, patient reluctance to endoscopy, unwillingness to continuing to use the drug, drug discontinuation more than two days, diseases that impair absorption ( cirrhosis, celiac disease).

**Age**

From **16 years** old to **85 years** old

**Gender**

Both

**Phase**

N/A

**Groups that have been masked**

*No information*

**Sample size**

Target sample size: **90**

**Randomization (investigator's opinion)**

Randomized

**Randomization description****Blinding (investigator's opinion)**

Single blinded

**Blinding description****Placebo**

Used

**Assignment**

Parallel

**Other design features**

If RUT test is positive triple therapy including amoxicillin, clarithromycin, omeprazole is prescribed for two weeks. According to ulcer size (greater than or equal to three centimeters or smaller than three centimeters) treatment time is determined. This way if the wound size is greater than or equal to three centimeters treatment with triple therapy for 2 weeks will be done and will be followed 4 weeks of treatment with omeprazole. If the wound size is smaller than 2 centimeters treatment with triple therapy for 2 weeks will be done and will be followed 2 weeks of treatment with omeprazole. If RUT test is negative treatment just with omeprazole for 2 weeks is performed. Considering that in the case of ulcers in patients with gastrointestinal bleeding or in the case of PPI or antibiotic use in the last 2 weeks RUT answer may be false negative so in these cases gG H.PYLORI AB-I will be checked. If RUT is positive they will be treated as RUT positive and if RUT is negative they will be treated as RUT negative. Those who are in the intervention group in addition to triple therapy, zinc sulfate 220 mg capsules (Alhavi pharmaceutical company) will be given daily. And the people who are in the control group zinc sulfate 220 mg capsules will not be given.

**Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics Committee of Kurdistan University of Medical Sciences

**Street address**

Pasdaran St., Kurdistan University of Medical Sciences

**City**

Sanandaj

**Postal code****Approval date**

2014-03-05, 1392/12/14

**Ethics committee reference number**

14/47259

**Health conditions studied****1****Description of health condition studied**

Peptic ulcer

**ICD-10 code**

K27

**ICD-10 code description**

Peptic ulcer, site unspecified

**Primary outcomes****1****Description**

Ulcer size

**Timepoint**

6 weeks after initial endoscopy

**Method of measurement**

The ulcer would be determined by sub-specialist of gastroenterology via endoscopy

**Secondary outcomes****1****Description**

Complications

**Timepoint**

During the study and 8 weeks after the initial endoscopy

**Method of measurement**

Observation and examination by Subspecialist of Gastroenterology

**2****Description**

Ulcer place

**Timepoint**

During the initial endoscopy

**Method of measurement**

Based on the location of ulcer was determined by

gastroenterologist via endoscopy: stomach, antrum, fundus, cardia and duodenum.

### 3

#### **Description**

Diarrhea and vomiting

#### **Timepoint**

During the study

#### **Method of measurement**

Observation and examination by specialist

### 4

#### **Description**

Dizziness

#### **Timepoint**

During the study

#### **Method of measurement**

Observation and examination by specialist

## **Intervention groups**

### 1

#### **Description**

In addition to triple therapy, Zinc sulfate 220 mg capsules (Alhavi pharmaceutical company) will be given to people who are in the intervention group daily.

#### **Category**

Treatment - Drugs

### 2

#### **Description**

The control group received placebo capsules in addition to triple therapy.

#### **Category**

Treatment - Drugs

## **Recruitment centers**

### 1

#### **Recruitment center**

##### **Name of recruitment center**

Tohid Hospital

##### **Full name of responsible person**

Morteza Nayebi

##### **Street address**

Basij Sq., Geryashan St., Tohid Hospital

##### **City**

Sanandaj

## **Sponsors / Funding sources**

### 1

#### **Sponsor**

##### **Name of organization / entity**

Vice Chancellor for Research, Kurdistan University of Medical Sciences

#### **Full name of responsible person**

Fardin Gharibi

#### **Street address**

Pasdaran St., Kurdistan University of Medical Sciences

#### **City**

Sanandaj

#### **Grant name**

#### **Grant code / Reference number**

#### **Is the source of funding the same sponsor organization/entity?**

Yes

#### **Title of funding source**

Vice Chancellor for Research, Kurdistan University of Medical Sciences

#### **Proportion provided by this source**

100

#### **Public or private sector**

*empty*

#### **Domestic or foreign origin**

*empty*

#### **Category of foreign source of funding**

*empty*

#### **Country of origin**

#### **Type of organization providing the funding**

*empty*

## **Person responsible for general inquiries**

#### **Contact**

##### **Name of organization / entity**

Kurdistan University of Medical Sciences

##### **Full name of responsible person**

Morteza Nayebi

##### **Position**

Resident of Internal Medicine

##### **Other areas of specialty/work**

##### **Street address**

Basij Sq., Geryashan St., Tohid Hospital

##### **City**

Sanandaj

##### **Postal code**

##### **Phone**

+98 87 3366 4654

##### **Fax**

##### **Email**

mortazanayebi55@yahoo.com

##### **Web page address**

## **Person responsible for scientific inquiries**

#### **Contact**

##### **Name of organization / entity**

Kurdistan University of Medical Sciences

##### **Full name of responsible person**

Dr Kambiz Yazdanpanah

##### **Position**

Associate Professor

##### **Other areas of specialty/work**

##### **Street address**

Pasdaran St., Kurdistan University of Medical Sciences

##### **City**

Sananadaj  
**Postal code**  
**Phone**  
+98 87 3366 4651  
**Fax**  
**Email**  
KYZDAN4@YAHOO.COM  
**Web page address**

## Person responsible for updating data

### Contact

**Name of organization / entity**  
Kurdistan University of Medical Sciences  
**Full name of responsible person**  
Morteza Nayebi  
**Position**  
Resident of Internal Medicine  
**Other areas of specialty/work**  
**Street address**  
Basij Sq., Geryashan St., Tohid Hospital  
**City**  
Sananadaj  
**Postal code**

**Phone**  
+98 87 3366 4652  
**Fax**  
**Email**  
mortazanayebi55@yahoo.com  
**Web page address**

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*